Skip to content

Immediate Effects of STENDO on the Walking Abilities of Patients with COPD (STENDO-COPD)

Immediate Effects of STENDO on the Walking Abilities of Patients with COPD

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05618509
Acronym
STENDO-COPD
Enrollment
32
Registered
2022-11-16
Start date
2023-01-04
Completion date
2024-05-27
Last updated
2024-09-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COPD, Walking Performance

Brief summary

The STENDO process is a heart rate synchronized massage system initially validated for the treatment of lymphedema. It is a combination enveloping the lower limbs up to the abdomen. The massage system induces pressure from the ankles to the abdomen between each heartbeat. This technique would also allow an improvement of endothelial function by a greater release of nitric oxide. Thus the capacity for physical exercise is potentially improved. The use of STENDO has never been evaluated in COPD (Chronic obstructive pulmonary disease) where physical capacity is impaired with, in particular, the presence of endothelial dysfunction. STENDO may improve walking performance. If these hypotheses are validated, the STENDO could be positioned as a complement to the exercise rehabilitation strategies offered to symptomatic COPD patients.

Interventions

DEVICESTENDO session

It is a combination enveloping the lower limbs up to the abdomen. The massage system induces pressure from the ankles to the abdomen between each heartbeat. The capacity for physical exercise is potentially improved. STENDO : 45 minutes, 2 legs and the pelvis, pression of 65mm Hg

OTHERA six-minute walking distance test

Before and after STENDO session, the patient has to walk 6 minutes in a flat corridor (30m long)

OTHERNear Infrared Spectroscopy

The goal is to measure the evolution of the oxygen consumption of the right leg during an effort on a bicycle at constant power for 5 minutes.

DEVICESTENDO placebo

STENDO placebo : 45 minutes, on 2 legs and the pelvis, pression of 10 mmHg

Sponsors

European Clinical Trial Experts Network
CollaboratorOTHER
Elsan
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Symptomatic chronic obstructive pulmonary disease (COPD) attested by a Tiffeneau ratio \<70% * Not oxygen dependent * Oriented for an ambulatory effort rehabilitation program in after-care and rehabilitation * Negative urine pregnancy test in women of childbearing age * Affiliation to a social security scheme or beneficiary of such a scheme * Patient having signed the free and informed consent

Exclusion criteria

* Neurological or osteo-articular pathology impeding walking. * Dementia with MMSE (Mini mental state examination) \<24/30 * Heart failure * Covid + in the previous 3 months * Major surgery in the year preceding the session * Heavy abdominal, pelvic and lower limb cosmetic surgery in the year preceding the session * Impaired comprehension and/or expression * Being simultaneously on oral contraception (pill) and smoking (more than 10 cigarettes per day) * Severe unbalanced high blood pressure * severe peripheral neuropathy * Colostomy * Open fracture, bleeding or healing wound * 3rd degree burn * Liver cirrhosis * Bedsore * Have prohibitions and restrictions with a history of phlebitis or recent progressive venous thrombosis (less than 6 months) or arterial disease of the lower limbs stage 3 and 4 * Refusal to participate in the study

Design outcomes

Primary

MeasureTime frame
Variation in the 6-minute walk test distance after the performance of the STENDO/STENDO Placebo session compared to the value of the initial 6-minute walk test..Baseline to immediately after STENDO/STENDO Placebo procedure

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026